JAK
Los inhibidores de la Janus quinasa (JAK) son compuestos que se dirigen a la vía de señalización JAK-STAT, la cual está involucrada en el crecimiento celular, la respuesta inmunitaria y la angiogénesis. Al inhibir JAK, estos compuestos pueden reducir la señalización que conduce a la formación de nuevos vasos sanguíneos en los tumores, inhibiendo así el crecimiento tumoral. Los inhibidores de JAK son importantes en el tratamiento del cáncer y las enfermedades inflamatorias. En CymitQuimica, ofrecemos una amplia gama de inhibidores de JAK de alta calidad para apoyar su investigación en oncología, inmunología y angiogénesis.
Se han encontrado 245 productos de "JAK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
XL019
CAS:<p>XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.</p>Fórmula:C25H28N6O2Pureza:99.19%Forma y color:SolidPeso molecular:444.532,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:<p>2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.</p>Fórmula:C16H13Cl2N3O2Pureza:98.77%Forma y color:SolidPeso molecular:350.2Cerdulatinib
CAS:<p>Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.</p>Fórmula:C20H27N7O3SPureza:98.74% - 99.49%Forma y color:SolidPeso molecular:445.54Protosappanin A
CAS:<p>Protosappanin A combats brain inflammation, suppresses rat heart transplant rejection, fights MRSA, and inhibits HIV with a 12.6 uM IC50.</p>Fórmula:C15H12O5Pureza:99.42% - 99.82%Forma y color:SolidPeso molecular:272.25AMG-47a
CAS:<p>AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.</p>Fórmula:C29H28F3N5O2Pureza:98%Forma y color:SolidPeso molecular:535.56Decernotinib
CAS:<p>Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.</p>Fórmula:C18H19F3N6OPureza:99.28% - >99.99%Forma y color:SolidPeso molecular:392.38G5-7
CAS:<p>G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.</p>Fórmula:C22H19F2NO3Pureza:97.3%Forma y color:SolidPeso molecular:383.39(E/Z)-Zotiraciclib
CAS:<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.</p>Fórmula:C23H24N4OPureza:97.75% - 99.92%Forma y color:SolidPeso molecular:372.46FLLL32
CAS:<p>FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).</p>Fórmula:C28H32O6Pureza:97% - 97.90%Forma y color:SolidPeso molecular:464.55AG490
CAS:<p>AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.</p>Fórmula:C17H14N2O3Pureza:98.6% - 99.39%Forma y color:Yellow SolidPeso molecular:294.3GDC-0214
CAS:<p>GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).</p>Fórmula:C28H28ClF2N9O3Pureza:99.75%Forma y color:SolidPeso molecular:612.03Baricitinib
CAS:<p>Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.</p>Fórmula:C16H17N7O2SPureza:99% - >99.99%Forma y color:SolidPeso molecular:371.42Peficitinib
CAS:<p>Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.</p>Fórmula:C18H22N4O2Pureza:98.67% - 99.4%Forma y color:SolidPeso molecular:326.39Pyridone 6
CAS:<p>Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).</p>Fórmula:C18H16FN3OPureza:97.1% - 98.74%Forma y color:SolidPeso molecular:309.34WHI-P97
CAS:<p>WHI-P97 is a rationally designed potent inhibitor of JAK-3.</p>Fórmula:C16H13Br2N3O3Pureza:99.93%Forma y color:SolidPeso molecular:455.1JANEX-1
CAS:<p>JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.</p>Fórmula:C16H15N3O3Pureza:98% - 99.81%Forma y color:SolidPeso molecular:297.31WP1066
CAS:<p>WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.</p>Fórmula:C17H14BrN3OPureza:98.92% - 99.73%Forma y color:SolidPeso molecular:356.22Fedratinib hydrochloride hydrate
CAS:<p>Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.</p>Fórmula:C27H40Cl2N6O4SPureza:98.96% - 99.87%Forma y color:SolidPeso molecular:615.61AZ960
CAS:<p>AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).</p>Fórmula:C18H16F2N6Pureza:96.02% - 98.51%Forma y color:SolidPeso molecular:354.36ZM39923 hydrochloride
CAS:<p>ZM39923 hydrochloride (JAK3 Inhibitor IV) is an JAK1/3 inhibitor, almost no activity to JAK2 and modestly potent to EGFR; also is sensitive to transglutaminase.</p>Fórmula:C23H25NO·HClPureza:98.05%Forma y color:SolidPeso molecular:367.91BMS-911543
CAS:<p>BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.</p>Fórmula:C23H28N8OPureza:97.69% - 99.98%Forma y color:SolidPeso molecular:432.52SAR-20347
CAS:<p>SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).</p>Fórmula:C21H18ClFN4O4Pureza:98.99% - 99.77%Forma y color:SolidPeso molecular:444.84FM-381
CAS:<p>FM381, a JAK3 inhibitor with 127 pM IC50, is 410-3600x more selective over JAK1/2/TYK2.</p>Fórmula:C24H24N6O2Pureza:98.44%Forma y color:SolidPeso molecular:428.49TG101209
CAS:<p>TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.</p>Fórmula:C26H35N7O2SPureza:99% - >99.99%Forma y color:SolidPeso molecular:509.67Deucravacitinib
CAS:Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.Fórmula:C20H19D3N8O3Pureza:98.52% - >99.99%Forma y color:SolidPeso molecular:425.46RO495
CAS:<p>RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays</p>Fórmula:C17H14Cl2N6OPureza:97.94%Forma y color:SolidPeso molecular:389.24SC99
CAS:SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.Fórmula:C15H8Cl2FN3OPureza:99.56%Forma y color:SolidPeso molecular:336.15Brevilin A
CAS:<p>Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.</p>Fórmula:C20H26O5Pureza:99.97% - >99.99%Forma y color:SolidPeso molecular:346.42Cerdulatinib hydrochloride
CAS:<p>Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.</p>Fórmula:C20H28ClN7O3SPureza:99.85%Forma y color:SolidPeso molecular:482GS-829845
CAS:<p>GS-829845 is a JAK1 inhibitor, the main component of the active metabolite of Filgotinib, which is approximately 10-fold less potent and has a longer half-life</p>Fórmula:C17H19N5O2SPureza:99.93%Forma y color:SolidPeso molecular:357.43NVP-BSK805
CAS:<p>NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.</p>Fórmula:C27H28F2N6OPureza:98%Forma y color:SolidPeso molecular:490.55Solrikitug
CAS:<p>Solrikitug,Anti-CRLF2 humanized IgG1κ monoclonal antibody.</p>Pureza:95%Forma y color:LiquidZM39923
CAS:<p>ZM39923 is a JAK3 inhibitor (pIC50: 7.1). ZM39923 also effectively inhibits tissue transglutaminase (IC50: 10 nM).</p>Fórmula:C23H25NOPureza:98%Forma y color:SolidPeso molecular:331.45(3S,4S)-Tofacitinib
CAS:<p>(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.</p>Fórmula:C16H20N6OPureza:98%Forma y color:SolidPeso molecular:312.37SD-1029
CAS:<p>SD-1029 is a JAK2 inhibitor and a novel Stat3 activation inhibitor that inhibits Stat3 phosphorylation and JAK-STAT signaling.</p>Fórmula:C25H32Br2Cl2N2O3Forma y color:SolidPeso molecular:639.25JAK-IN-11
CAS:<p>JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.</p>Fórmula:C23H22FN5O4SPureza:99.75%Forma y color:SolidPeso molecular:483.52JAK-IN-20
CAS:<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>Fórmula:C28H30FN7O2Forma y color:SolidPeso molecular:515.58JAK-2/3-IN-2
CAS:<p>JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 & JAK3 inhibitor with IC50s of 23.85 nM (JAK2) & 18.9 nM (JAK3).</p>Fórmula:C19H19ClN2OSForma y color:SolidPeso molecular:358.89Peficitinib hydrochloride
CAS:<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>Fórmula:C18H23ClN4O2Forma y color:SolidPeso molecular:362.86TK4b
CAS:<p>TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).</p>Fórmula:C21H22N2O2Forma y color:SolidPeso molecular:334.41TK4g
CAS:<p>TK4g, a potent JAK inhibitor, has IC50s of 12.61 nM (JAK2) & 15.80 nM (JAK3); promising for lymphoid diseases & leukemia research.</p>Fórmula:C19H19N3O4SForma y color:SolidPeso molecular:385.44JAK-IN-14
CAS:<p>JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.</p>Fórmula:C19H15FN4OPureza:98.27%Forma y color:SolidPeso molecular:334.35TyK2-IN-2
CAS:<p>TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).</p>Fórmula:C16H18N6OPureza:98%Forma y color:SolidPeso molecular:310.35JAK-IN-18
CAS:<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>Fórmula:C27H28F2N6O3Forma y color:SolidPeso molecular:522.55JAK3-IN-12
CAS:<p>JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.</p>Fórmula:C19H19N5O4SForma y color:SolidPeso molecular:413.45Tyk2-IN-5
CAS:<p>Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).</p>Fórmula:C21H19FN8O2Pureza:98%Forma y color:SolidPeso molecular:434.43EP009
CAS:<p>EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.</p>Fórmula:C14H24O2Forma y color:SolidPeso molecular:224.34Tyk2-IN-7
CAS:<p>Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).</p>Fórmula:C18H15D3N6O3SPureza:98%Forma y color:SolidPeso molecular:401.46MS-1020
CAS:<p>MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.</p>Fórmula:C21H18N2O3Pureza:98%Forma y color:SolidPeso molecular:346.381,2,3,4,5,6-Hexabromocyclohexane
CAS:<p>Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.</p>Fórmula:C6H6Br6Pureza:98%Forma y color:SolidPeso molecular:557.54
